β0 788β γ599 Fax: +44 (0)β0 788β γ884 Conflict of Interest: The authors declare no conflicts of interest exist.
Introduction
Germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSHβ, MSH6 and PMSβ can lead to Lynch Syndrome, an autosomal condition also known as hereditary non polyposis colorectal cancer (HNPCC) (1) . Patients with this condition have an 80% lifetime risk of developing colorectal cancer and a 60% lifetime risk of developing endometrial cancer. In addition, patients are also at an increased risk of developing other cancers such as small bowel, pancreatic, prostate, urinary tract, liver, kidney, and bile duct cancer. Defects in the MMR system can also occur as a result of somatic mutations or epigenetic silencing. Significantly, it is thought that 15% of all colorectal cancers and γ0% of all endometrial cancers have loss of a functional MMR pathway (2, 3) . Furthermore, mutations in the MMR gene, MSH6 have been identified in β6-41% of temozolomide-resistant glioblastoma (GBM) patients and mediate temozolomide resistance (4) (5) (6) . More recently, a number of studies have shown that a reduction in MMR protein levels, in particular MSHβ and MSH6, occurs upon GBM recurrence and that transcript levels of MMR genes are prognostic for patient survival after temozolomide treatment (6) (7) (8) .
Synthetic lethality with loss of DNA repair proteins has previously been successfully exploited (9) (10) (11) (12) (13) . To date, a number of studies have identified synthetic lethal interactions with specific MMR gene mutations or specific tumor types (9, 10, 14, 15) . In this study, we carried out drug-repositioning compound screens in a panel of MMR-deficient cellular models from a range of different tumor types, to identify drugs that sensitize with MMR loss in general. We identified the potassium-sparing diuretic drug, Triamterene as a novel therapeutic agent in MMR-deficient tumor cells. Our data suggest that the selectivity of Triamterene is based on its anti-folate activity and is dependent on expression of the folate synthesis enzyme, thymidylate synthase. Taken together, our data reveals that Triamterene is a promising novel therapeutic strategy for the treatment of MMR-deficient disease in a range of different tumor types.
Materials and Methods

Cell lines
The Uβ51.TRγ GBM cell lines were a kind gift from Dr. David Louis (Massachusetts General Hospital, MA, USA). In the original paper (5) , the nomenclature for these cell lines was A17β.TRγ. In a subsequent correction to the paper, this nomenclature was updated to Uβ51.TRγ (MSH6-) (16) . We have STR profiled these cell lines and confirm (MMR+) were a kind gift from Dr. Alan Clark (NIEHS). DLD1 and DLD1+Chrβ cells were grown in RPMI (Sigma-Aldrich), 10% FBS and 1% penicillin-streptomycin at γ7 °C with 5% CO β . All other cell lines were grown in DMEM (Sigma-Aldrich), 10% FBS and 1% penicillin-streptomycin at γ7 °C with 5% CO β . DLD1+Chrβ and HCT116+Chrγ cells were maintained under selective pressure of 400 µg/mL geneticin (G418 sulfate, Roche).
Uβ51.TRγ cells were maintained in 100 µM TMZ (Santa Cruz). All cell lines were authenticated on the basis of STR-profile, viability, morphologic inspection, and were routinely mycoplasma tested.
Compound Library Screen
The FDA-approved compound library incorporating 11β0 drugs was purchased from Selleck Chemicals. Cells were plated in 96-well plates and treated with vehicle (0.01% DMSO) or the compound library (average compound concentration of the library in media was 10 µM). After 4 days incubation with the drug library, cell viability was assessed using the CellTiter Glo assay (Promega) according to the manufacturer's instructions. Luminescence readings from each well were log transformed and normalized according to the median signal on each plate and then standardized by use of a Z-score statistic, using the median absolute deviation to estimate the variation in each screen. Z-scores were compared to identify compounds that cause selective loss of viability in MMR-deficient cells, in comparison to MMR-proficient cells. For validation experiments, cells were treated with increasing concentrations of Triamterene and cell viability using the CellTiter Glo assay was assayed after 5 days. Triamterene was purchased from Sigma-Aldrich. N-acetyl cysteine was purchased from Santa Cruz.
Colony formation assay
Validation of Triamterene was performed by colony formation assays. Cells were seeded at various densities in six-well plates and exposed to the drug at the indicated concentrations. Cells were retreated every four days, whereby the drug containing media was removed and the fresh drug containing media was added. After ten to fourteen days, cells were fixed and stained with sulphorhodamine-B (Sigma, St. Louis, USA) and counted.
Cell Cycle Analysis
Following Triamterene treatment, cells were fixed in 70% ice-cold ethanol and stained with 4% propidium iodide (PI) and 10% RNase A in PBS for cell-cycle analysis. The sample readout was performed on the BD LSRFortessa (Becton Dickinson, USA), and the data were analysed using FlowJo (FlowJo LLC).
Xenograft experiments
DLD1 and DLD1+Chrβ cell lines (1.6 x 10 6 cells) re-suspended in PBS, were injected subcutaneously into the right flank of adult (~10 weeks old) male NOD-SCID mice (Charles-River Laboratories). Tumors were allowed to develop to a mean tumor diameter between 4 and 8 mm before treatment. Mice were then treated γ times a week by gavage, with β5 mg/kg Triamterene or vehicle. Tumors were measured twice weekly.
Mice were sacrificed in case of sickness or when the tumors reached 1.44cm β . All animal procedures were carried out as per the Animal Scientific Procedures Act 1986, under the Home Office approval licenses (PPL-70/7β75 and PIL-70/βγ444).
Protein analysis
Cell pellets were lysed in β0 mM Tris (pH 8), β00 mM NaCl, 1 mM EDTA, 0.5% (v/v) NP40, 10% glycerol, supplemented with protease inhibitors. For western blotting, lysates were electrophoresed on Novex precast gels (Invitrogen) and immunoblotted using the following antibodies: anti-MSH6 (#54β4), anti-MSHβ (#β017), anti-MLH1 (#4β56), antithymidylate synthase (#9045), β-Actin (#4970), purchased from Cell Signaling. The following antibodies were also used; anti-MSHγ (sc-11441; Santa Cruz) and anti βtubulin (T8γβ8; Sigma). This was followed by incubation with anti-IgG-horseradish peroxidase and chemiluminescent detection (Supersignal West Pico Chemiluminescent Substrate, Pierce). Immunoblotting for β-Actin and β-tubulin were performed as loading control.
siRNA transfections
For siRNA transfections, cells were transfected with individual siRNA oligos (Qiagen) using Lipofectamine RNAiMax (Invitrogen) according to the manufacturer's instructions.
As a control for each experiment, cells were left un-transfected or transfected with a nontargeting control siRNA and concurrently analyzed. 
Reactive Oxygen Species Detection
Detection of cellular DNA damage by Comet assay
A commercially available Comet assay kit from Cell Biolabs (STA-γ51) was used to measure levels of cellular DNA damage. The assays were performed according to the manufacturer's instructions. Briefly, 1 x 10 5 cells were mixed with molten agarose. DNA from embedded cells was then denatured in an alkaline solution. Samples were electrophoresed in a horizontal chamber to separate intact DNA from damaged fragments. Following electrophoresis, samples were then stained with a Vista Green DNA dye, and visualized by fluorescence microscopy. Cellular DNA damage is visualised as it migrates further than intact DNA and results in a comet tail shape. For assessment of the Comet assay, 50 comets were scored per condition and ImageJ was used to quantify the intensity and score the comets using the following calculation: Tail DNA % = 100 X Tail DNA Intensity/Cell DNA intensity.
Estimation of 8-oxodG levels
A commercially available ELISA kit from Cell Biolabs (STA-γβ0) was used to measure levels of 8oxodG. Although this 8-oxodG ELISA has potential shortcomings for the precise quantification of 8-oxodG levels, it allows an estimation of the change of 8-oxodG levels upon triamterene treatment. Genomic DNA was extracted using the QIamp DNA isolation kit (Qiagen), digested with nuclease P1, treated with calf intestinal phosphatase and denatured. To avoid artifactual production of 8-oxodG, we used a phenol-free method of DNA isolation and DNA was completely digested. The assays were performed according to the manufacturer's instructions. Briefly, 10-15 µg DNA from untreated and treated cells or the 8oxodG standard (0.078-β0 ng/ml) was incubated with an 8oxodG monoclonal antibody in an 8oxodG-precoated microtiter plate. The assay was normalized by using an equal amount of DNA for each sample. Standard curves were calculated with serial dilutions of 8oxodG standard to calculate reaction efficiency. Samples were assayed in triplicate.
Detection of γH2AX Foci by immunofluorescence
Cells were seeded onto poly-lysine coated coverslips and treated with drugs as indicated. After 48 hrs treatment, cells were fixed for 10 min with 4% PFA in PBS. Cells were then permeabilized with Triton, blocked for 1 h at room temperature and subsequently incubated with γHβAX antibody (#05-6γ6, Millipore) for 18 h at 4 °C . This was followed by incubation with anti-IgG-Alexa568 (#A110γ1, Invitrogen). Coverslips were then washed in 4% DAPI/1X PBS and mounted with ProLong® gold antifade mounting solution (Invitrogen). Slides were imaged using a Zeiss LSM 510 confocal microscope. Per condition, a minimum of γ00 cells were counted and quantified for HβAX positive cells (> 5 foci per nucleus).
Statistical analysis
Unless otherwise stated, data represent standard error of the mean of at least three independent experiments. The two-tailed paired Student's t test was used to determine statistical significant with p<0.05 regarded as significant. For confocal experiments, images are representative of at least three independent experiments, where a minimum of γ00 cells were analyzed.
Results
MMR deficiency increases the toxicity of triamterene in a range of tumor-derived cell lines
To identify compounds that can sensitize MMR-deficient cells, we screened a large panel of cell lines with a range of different MMR gene mutations from a number of tumor types. These included the MSH6-deficient colorectal cancer cell lin e DLD1 and its isogenic MSH6-proficient DLD1+Chrβ cell line ( Figure 1A) , the previously characterized temozolomide-resistant MSH6-deficient Uβ51.TRγ GBM cell line and the isogenic MSH6-proficient Uβ51 cell line ( Figure 1B ; (5, 16) ) and a panel of endometrial cancer cell
ISHIKAWA (MLH1-deficient) and HEC1B (MSH6-deficient; Figure 1C ). Figure 1G ).
To further investigate this selectivity for MMR deficiency, we measured cell viability of the MLH1-deficient colorectal cancer cell line HCT116 and its isogenic matched-paired MLH1-proficient cell line, HCT116+Chrγ when treated with Triamterene ( Figure 1H ).
Significantly, Triamterene also induced selectivity in the MLH1-deficient HCT116 cells, but not in MLH1-proficient cells. Significantly, we observed selectivity in all MMR deficient cell lines tested, regardless of MMR mutation or tumor type, while no significant effect was observed in MMR-proficient cells. This suggests that Triamterene is selective with loss of MMR pathway function and may provide a novel therapeutic strategy in a wide range of cancers.
Triamterene cytotoxicity occurs through its antifolate activity and requires thymidylate synthase expression
Previous studies have shown that Triamterene can act as both an inhibitor of the epithelial sodium channel (ENaC) (17) and also as an antifolate (18) . Therefore, to 1γ determine the mechanism underlying the observed Triamterene-induced cytotoxicity with MMR-deficiency, we performed siRNA-mediated depletion of a panel of ENaC isoforms (α, β & γ) previously suggested to be inhibited by Triamterene and analyzed cell viability ( Figure βA) . We observed no differential cytotoxicity upon targeting the ENaC isoforms, either alone or in combination, which suggests that the observed selectivity is not due to ENaC inhibition. We next determined whether Triamterene-mediated selectivity was due to its anti-folate activity. To this end, we measured the cell viability of MMR-deficient and proficient cells treated with folates (dihydrofolate and tetrahydrofolate) in addition to
Triamterene. We observed that the selectivity of Triamterene for MMR deficiency could be rescued by the addition of folates (Figure βB & βC) , therefore suggesting that Triamterene is selective through its anti-folate activity.
To further analyze the anti-folate effect of Triamterene, we analyzed the requirement for Figure 1A) . These results suggest that thymidylate synthase expression is necessary for the Triamterene-mediated selectivity in MMR-deficient cells.
Furthermore, treatment with the clinically approved thymidylate synthase inhibitors, 5-FU and Raltitrexed, also rescued the Triamterene-induced cytotoxicity in MMR-deficient cells (Supplementary Figure 1B) . Taken together, our results suggest that Triamtereneinduced selectivity is due to the anti-folate activity of Triamterene and is dependent on thymidylate synthase expression.
Triamterene-induced cytotoxicity depends on increased ROS levels
It has previously been shown that folate starvation can increase ROS levels, leading to cellular oxidative stress (19) . Our previous studies have shown that an increase in oxidative stress is synthetically lethal with MMR deficiency (9, 10, 14, 15) . Therefore, we Figure 4D ).
Triamterene can re-sensitize MMR-deficient cells in vivo
To examine the in vivo efficacy of Triamterene, the MMR-deficient and MMR-proficient DLD1 and DLD1+Chrβ, respectively, colorectal cancer cells, were injected subcutaneously into NOD-SCID mice. Xenografted mice were subjected to treatment γ times a week with Triamterene or vehicle (PBS). We observed that tumor growth from the MMR-deficient xenografts was significantly reduced (p=0.01) by Triamterene treatment when compared to vehicle ( Figure 6A ). In addition, no difference in tumor growth was observed in the Triamterene treated MMR-proficient xenograft tumors when compared to vehicle, further validating Triamterene as a compound that specifically targets cancer cells with deficient MMR pathways ( Figure 6B ). Taken together, these in vivo observations further indicate that Triamterene treatment has potential clinical utility in patients with MMR-deficient, for which therapeutic options are scarce.
DISCUSSION
Through a compound screen, we identified the diuretic drug Triamterene as an in vitro and in vivo selective compound with MMR deficiency. Collectively, our data argues that stratifying patients according to their MMR status would prove efficacious with regards to treatment with Triamterene. Furthermore, our data suggests that levels of thymidylate synthase govern sensitivity to Triamterene in MMR-deficient cells. Upon thymidylate synthase inhibition, treatment with Triamterene was no longer selective suggesting that thymidylate synthase levels determine the balance between Triamterene resistance and sensitivity in these cells. Our data suggest that folate inhibition and thymidylate synthase are critical for the triamterene selectivity in MMR-deficient cells, however we cannot exclude the fact that other pathways may also be influencing this effect, at least in part.
One of the most intriguing findings from this work is the requirement for thymidylate synthase for the induction of ROS upon Triamterene treatment. It is likely due to an activity of thymidylate synthase in the absence of sufficient levels of methyl donor CHβ-THF, thus leading to ROS. It would be interesting to understand whether thymidylate synthase is regulating ROS levels through NAPDH oxidase complexes or providing protection against ROS production through the antioxidant response. Numerous studies have investigated ROS induction upon treatment with thymidylate synthase inhibitors, but, to our knowledge, no study has identified a role for thymidylate synthase in the regulation of ROS levels. Previously, antifolate agents targeting the folate metabolic enzyme dihydrofolate reductase (DHFR), such as methotrexate and pemetrexed, were identified as cytotoxic in MSHβ-deficient cells, but not in other MMR-deficient cell lines (9, 20) . Perhaps this is due to the generation of specific DNA lesions upon DHFR inhibition in MSHβ-deficient cells, rather than a more general inhibition of folate metabolism upon Triamterene treatment. Taken together, these data also suggest a potential difference in the folate metabolic pathway in MMR-deficient and -proficient cell
lines.
An increase in ROS levels can lead to cellular DNA damage, including DNA fragmentation, oxidative DNA damage and ultimately an increase in DNA double strand breaks (DSB), thereby triggering cell cycle arrest. We observed a significant increase in cellular DNA damage, and more specifically 8-oxodG DNA lesions in the Triamterenetreated MMR-deficient cells only. Our data suggest that these lesions, if incompletely repaired, can induce DNA DSBs, which ultimately result in the cell cycle arrest and reduced cellular viability we observe.
We and others have focused largely on targeting loss of DNA repair in tumor cells.
However, recent advances indicate that targeting both the tumor cell and its interaction with the immune microenvironment may significantly improve patient benefit. A recent Phase II clinical trial in patients with deficiency in the MMR pathway indicated that MMR status predicted clinical benefit with the PD-1 inhibitor pembrolizumab (21). However, only 50% of MMR-deficient patients responded to pembrolizumab, suggesting that selectively targeting MMR-deficient tumor cells with for example Triamterene, in combination with immune checkpoint inhibitors may increase therapeutic efficacy and may prove to be more clinically beneficial.
In this study we exploit the concept of drug repurposing, which is the discovery of new indications for existing drugs, to identify novel selective drugs for the treatment of MMRdeficient tumors. Repositioning of drugs highlights an increasingly effective means of drug discovery. In addition to the reduced cost and time commonly associated with traditional drug discovery, the advantage of drug repositioning strategies is the fact that existing drugs have already been used in patients and, therefore, their toxicity and safety profiles are already established. Hence, drugs identified in drug repositioning approaches can enter clinical trials rapidly, thereby maximizing their potential benefit to patients. Here, we have shown for the first time that Triamterene, originally developed as a diuretic, has anti-tumor activity and we provide evidence of its efficacy in a range of MMR-deficient tumor types.
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